A randomized trial investigating the superiority of TDM-optimized teicoplanin dosing versus standard of care

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503411-15-00

Acronym

113998

Enrollment

Registered

2023-06-01

Start date

2023-08-17

Completion date

Unknown

Last updated

2025-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Brief summary

• The difference in fraction of patients reaching pharmacokinetic target attainment of unbound teicoplanin concentrations at 5 days after start of treatment of the study group versus the control group.

Detailed description

• Time until reaching target attainment., • Incidence of clinical failure at day 30., • Total number of days in hospital, • Incidence of AKI during teicoplanin treatment

Interventions

DRUGTeicoplanin Hikma 400 mg Powder for solution for Injection/infusion or oral solution

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
• The difference in fraction of patients reaching pharmacokinetic target attainment of unbound teicoplanin concentrations at 5 days after start of treatment of the study group versus the control group.	—

Secondary

Measure	Time frame
• Time until reaching target attainment., • Incidence of clinical failure at day 30., • Total number of days in hospital, • Incidence of AKI during teicoplanin treatment	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026